32 −3.2 ± 7.4 −3.0 ± 8.3 13.44 ± 3.22 1.3 ± 6.2 1.8 ± 6.1 Inter-trochanter Cortical thickness (mm) 1.43 ± 0.26 0.9 ± 5.9 0.7 ± 6.4 1.51 ± 0.29 Poziotinib in vivo −2.3 ± 6.6 −0.8 ± 7.7 Cortical CSA (cm2) 1.38 ± 0.29 3.8 ± 7.4* 2.9 ± 8.6 1.54 ± 0.33 −1.6 ± 5.6 −0.6 ± 5.5 Total CSA (cm2) 2.38 ± 0.45 3.8 ± 8.8* 4.7 ± 9.4* 2.59 ± 0.5 −1.8 ± 5.6 −0.6 ± 4.8 Cortical perimeter (cm) 16.76 ± 1.15 0.2 ± 3.3 −0.6 ± 2.0 17.12 ± 1.18 0.6 ± 2.4 0.0 ± 2.1 Cortical vBMD (mg/cm3) 638.96 ± 48.01 −0.4 ± 2.4 −1.5 ± 2.1** 646.03 ± 44.09 −0.3 ± 2.9 −0.6 ± 2.4 Total vBMD (mg/cm3) 186.13 ± 35.97 1.1 ± 3.3 0.7 ± 4.7 196.1 ± 35.7 −1.5 ± 4.5

−1.5 ± 4.8 SM (cm3) 0.67 ± 0.18 5.0 ± 15.8 4.1 ± 11.8 0.73 ± 0.18 2.4 ± 12.0 1.8 ± 10.2 BR 19.71 ± 3.6 2.1 ± 10.2 1.8 ± 10.7 19.26 ± 4.41 4.3 ± 9.5* 2.1 ± 10.1 Femoral shaft Cortical thickness (mm) 3.71 ± 0.62 0.7 ± 5.1 2.6 ± 4.5* 3.91 ± 0.62 −0.7 ± 4.6 −1.3 ± 3.9 Cortical CSA (cm2) 2.22 ± 0.39 1.7 ± 5.2 2.7 ± 3.6* 2.35 ± 0.39 −0.6 ± 4.1 −0.5 ± 3.0 Total CSA (cm2) 2.38 ± 0.38 1.7 ± 5.0 2.5 ± 3.4* 2.5 ± 0.39 −0.5 ± 4.0 −0.1 ± 3.0

Cortical perimeter (cm) 10.27 ± 0.6 0.4 ± 3.8 −0.7 ± 2.5 10.3 ± 0.7 0.2 ± 4.3 0.5 ± 3.2 Cortical vBMD (mg/cm3) 879.65 ± 70.77 0.4 ± 2.7 0.1 ± 3.6 892.97 ± 59.03 0.3 ± 4.1 −0.9 ± 3.1 Total vBMD (mg/cm3) 461.36 ± 77.37 0.7 ± 5.1 1.1 ± 5.7 482.05 ± 74.95 −0.2 ± 5.2 −1.4 ± 4.3 SM (cm3) 0.88 ± 0.18 1.3 ± 5.9 2.7 ± 7.2 0.93 ± 0.2 learn more −0.8 ± 5.2 0.3 ± 4.8 BR 3.67 ± 0.88 −0.4 ± 7.7 −3.3 ± 5.4* 3.39 ± 0.75 0.9 ± 6.7 1.9 ± 5.3 Data are mean ± SD QCT quantitated computed tomography, CSA cross-sectional area, vBMD volumetric bone mineral density, Branched chain aminotransferase SM section modulus, BR buckling ratio * p < 0.05; ** p < 0.01 compared with baseline Effect of teriparatide on cortical thickness, cortical and total CSA, and cortical perimeter compared to placebo Comparisons of cortical thickness, CSA, and perimeter between the two groups are shown in Fig. 1. Red and blue bars correspond to teriparatide and placebo groups, Selleck Idasanutlin respectively.